Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (414) 414
yttrium radioisotopes - therapeutic use (274) 274
animals (256) 256
science & technology (248) 248
tissue distribution (244) 244
yttrium radioisotopes - pharmacokinetics (235) 235
life sciences & biomedicine (234) 234
female (220) 220
mice (191) 191
male (188) 188
biological and medical sciences (178) 178
medical sciences (174) 174
radioimmunotherapy (162) 162
antibodies, monoclonal - therapeutic use (135) 135
radiology, nuclear medicine & medical imaging (129) 129
oncology (121) 121
radiopharmaceuticals - pharmacokinetics (119) 119
middle aged (117) 117
antibodies, monoclonal - pharmacokinetics (110) 110
mice, nude (100) 100
adult (94) 94
aged (94) 94
radiopharmaceuticals - therapeutic use (94) 94
tumors (90) 90
radioimmunotherapy - methods (84) 84
yttrium radioisotopes - administration & dosage (83) 83
pharmacology. drug treatments (82) 82
radiotherapy dosage (80) 80
yttrium radioisotopes (76) 76
radionuclide imaging (68) 68
yttrium (66) 66
dosimetry (65) 65
antineoplastic agents (57) 57
radioisotopes (53) 53
treatment outcome (53) 53
cell line, tumor (49) 49
indium radioisotopes - pharmacokinetics (48) 48
yttrium radioisotopes - chemistry (48) 48
microspheres (47) 47
octreotide - analogs & derivatives (47) 47
rats (47) 47
indium radioisotopes - therapeutic use (46) 46
radiotherapy (44) 44
liver neoplasms - radiotherapy (43) 43
neoplasm transplantation (43) 43
radiation dosage (43) 43
cancer (42) 42
transplantation, heterologous (42) 42
yttrium-90 (41) 41
mice, inbred balb c (40) 40
dose-response relationship, radiation (39) 39
nuclear medicine (39) 39
radiation therapy (38) 38
octreotide - pharmacokinetics (37) 37
radiometry - methods (37) 37
yttrium radioisotopes - adverse effects (37) 37
lymphoma, non-hodgkin - radiotherapy (36) 36
immunotherapy (35) 35
indium radioisotopes (35) 35
antibodies, monoclonal - administration & dosage (34) 34
iodine radioisotopes - therapeutic use (34) 34
positron-emission tomography (34) 34
radioisotopes - therapeutic use (34) 34
radiopharmaceuticals - administration & dosage (34) 34
liver (33) 33
monoclonal antibodies (33) 33
neoplasms - radiotherapy (33) 33
pentetic acid - analogs & derivatives (33) 33
tumor cells, cultured (33) 33
liver neoplasms - diagnostic imaging (31) 31
octreotide - therapeutic use (31) 31
pentetic acid - pharmacokinetics (31) 31
pharmacology & pharmacy (31) 31
medicine & public health (30) 30
radiometry (30) 30
time factors (30) 30
organometallic compounds - pharmacokinetics (29) 29
xenograft model antitumor assays (29) 29
antibodies, monoclonal - immunology (28) 28
immunoconjugates - pharmacokinetics (28) 28
immunoconjugates - therapeutic use (28) 28
isotope labeling (28) 28
radioisotopes - pharmacokinetics (28) 28
aged, 80 and over (27) 27
radiopharmaceuticals (27) 27
radiotherapy. instrumental treatment. physiotherapy. reeducation. rehabilitation, orthophony, crenotherapy. diet therapy and various other treatments (27) 27
metabolic clearance rate (26) 26
tomography, x-ray computed (26) 26
treatment. general aspects (26) 26
abridged index medicus (25) 25
drug stability (25) 25
liver neoplasms - secondary (25) 25
models, biological (25) 25
care and treatment (24) 24
combined modality therapy (24) 24
imaging / radiology (24) 24
iodine radioisotopes - pharmacokinetics (24) 24
medicine, research & experimental (24) 24
radioimmunotherapy - adverse effects (24) 24
research & experimental medicine (24) 24
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
by Kwekkeboom, Dik J and Kam, Boen L and van Essen, Martijn and Teunissen, Jaap J M and van Eijck, Casper H J and Valkema, Roelf and de Jong, Marion and de Herder, Wouter W and Krenning, Eric P
Endocrine-related cancer, ISSN 1351-0088, 3/2010, Volume 17, Issue 1, pp. R53 - R73
Review | Oncology | Endocrinology & Metabolism | Life Sciences & Biomedicine | Science & Technology | Humans | Digestive System Neoplasms - radiotherapy | Antineoplastic Agents - therapeutic use | Yttrium Radioisotopes - pharmacokinetics | Octreotide - pharmacokinetics | Digestive System Neoplasms - drug therapy | Gallium Radioisotopes - therapeutic use | Digestive System Neoplasms - diagnostic imaging | Neuroendocrine Tumors - diagnostic imaging | Receptors, Somatostatin - analysis | Organometallic Compounds - therapeutic use | Yttrium Radioisotopes - therapeutic use | Somatostatin - analogs & derivatives | Radiopharmaceuticals - pharmacokinetics | Octreotide - analogs & derivatives | Organometallic Compounds - pharmacokinetics | Treatment Outcome | Clinical Trials as Topic | Combined Modality Therapy | Indium Radioisotopes - pharmacokinetics | Positron-Emission Tomography - methods | Octreotide - therapeutic use | Somatostatin - pharmacokinetics | Peptides, Cyclic - pharmacokinetics | Neuroendocrine Tumors - radiotherapy | Animals | Organotechnetium Compounds - pharmacokinetics | Positron-Emission Tomography - standards | Receptors, Somatostatin - drug effects | Gallium Radioisotopes - pharmacokinetics | Neuroendocrine Tumors - drug therapy | Peptides, Cyclic - therapeutic use | Quality of Life | Indium Radioisotopes - therapeutic use | Somatostatin - therapeutic use | Radiopharmaceuticals - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Novel "add-on" molecule based on evans blue confers superior pharmacokinetics and transforms drugs to theranostic agents
by Chen, Haojun and Jacobson, Orit and Niu, Gang and Weiss, Ido D and Kiesewetter, Dale O and Liu, Yi and Ma, Ying and Wu, Hua and Chen, Xiaoyuan
Journal of Nuclear Medicine, ISSN 0161-5505, 04/2017, Volume 58, Issue 4, pp. 590 - 597
Albumin binding | Evans blue | Integrin | Theranostics | RGD peptide | Life Sciences & Biomedicine | Radiology, Nuclear Medicine & Medical Imaging | Science & Technology | Radiopharmaceuticals - chemistry | Radiopharmaceuticals - pharmacokinetics | Humans | Gene Expression Regulation, Neoplastic | Positron-Emission Tomography | Integrin alphaVbeta3 - metabolism | Tissue Distribution | Animals | Heterocyclic Compounds - chemistry | Heterocyclic Compounds, 1-Ring - chemistry | Radiochemistry | Cell Line, Tumor | Evans Blue - chemistry | Mice | Oligopeptides - chemistry | Yttrium Radioisotopes - therapeutic use | Copper Radioisotopes | Radiopharmaceuticals - therapeutic use | Drugs | Nuclear medicine | Pharmacology | Radiation therapy | Glycine | Drug development | Chemical compounds | Blood | Side effects | Arginine | Aspartic acid | Conjugation | Pharmacokinetics | Tumors | Half life | Tracers | Index Medicus | 90Y | integrin | albumin binding
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text 86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion
by Jamar, François and Barone, Raffaella and Mathieu, Isabelle and Walrand, Stéphan and Labar, Daniel and Carlier, Pascal and De Camps, Joëlle and Schran, Horst and Chen, TianLing and Smith, M. Charles and Bouterfa, Hakim and Valkema, Roelf and Krenning, Eric P and Kvols, Larry K and Pauwels, Stanislas
European journal of nuclear medicine and molecular imaging, ISSN 1619-7070, 4/2003, Volume 30, Issue 4, pp. 510 - 518
Amino acids Renal protection Peptide-based radiotherapy | Renal protection | Amino acids | Peptide-based radiotherapy | Yttrium Radioisotopes - urine | Humans | Middle Aged | Radiation-Protective Agents - administration & dosage | Male | Metabolic Clearance Rate | Yttrium Radioisotopes - pharmacokinetics | Amino Acids - administration & dosage | Octreotide - pharmacokinetics | Octreotide - urine | Arginine - administration & dosage | Tissue Distribution | Kidney - metabolism | Neuroendocrine Tumors - diagnostic imaging | Adult | Female | Octreotide - blood | Radiometry - methods | Yttrium Radioisotopes - adverse effects | Kidney - drug effects | Radiopharmaceuticals - pharmacokinetics | Octreotide - analogs & derivatives | Neuroendocrine Tumors - metabolism | Lysine - administration & dosage | Octreotide - adverse effects | Radiation Dosage | Yttrium Radioisotopes - blood | Organ Specificity | Amino Acids - adverse effects | Radiation Injuries - etiology | Cross-Over Studies | Dizziness - etiology | Vomiting - etiology | Aged | Tomography, Emission-Computed | Infusions, Intravenous | Radiation-Protective Agents - adverse effects | Drug Combinations | Cohort Studies | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Pharmacokinetics and Biodistribution of 111In- and 177Lu-Labeled J591 Antibody Specific for Prostate-Specific Membrane Antigen: Prediction of 90Y-J591 Radiation Dosimetry Based on 111In or 177Lu?
by Vallabhajosula, Shankar and Kuji, Ichei and Hamacher, Klaus A and Konishi, Shota and Kostakoglu, Lale and Kothari, Paresh A and Milowski, Mathew I and Nanus, David M and Bander, Neil H and Goldsmith, Stanley J
The Journal of nuclear medicine (1978), ISSN 0161-5505, 04/2005, Volume 46, Issue 4, pp. 634 - 641
Lu-labeled J591 monoclonal antibody | Y dosimetry | Antiprostate-specific membrane antigen antibody | Prostatic Neoplasms - metabolism | Prostatic Neoplasms - radiotherapy | Radioisotopes - pharmacokinetics | Humans | Middle Aged | Half-Life | Antibodies, Monoclonal - therapeutic use | Male | Metabolic Clearance Rate | Yttrium Radioisotopes - pharmacokinetics | Tissue Distribution | Aged, 80 and over | Lutetium - therapeutic use | Radiometry - methods | Yttrium Radioisotopes - therapeutic use | Lutetium - pharmacokinetics | Radiotherapy Dosage | Radioisotopes - therapeutic use | Radiopharmaceuticals - pharmacokinetics | Antibodies, Monoclonal - pharmacokinetics | Body Burden | Indium Radioisotopes - pharmacokinetics | Organ Specificity | Indium Radioisotopes - therapeutic use | Aged | Prostate-Specific Antigen - immunology | Relative Biological Effectiveness | Radiopharmaceuticals - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Evaluating the application of tissue-specific dose kernels instead of water dose kernels in internal dosimetry: A monte carlo study
by Khazaee Moghadam, Maryam and Kamali Asl, Alireza and Geramifar, Parham and Zaidi, Habib
Cancer biotherapy & radiopharmaceuticals, ISSN 1084-9785, 12/2016, Volume 31, Issue 10, pp. 367 - 379
tissue heterogeneity | Monte Carlo simulation | patient-specific dosimetry | dose point kernel | Life Sciences & Biomedicine | Radiology, Nuclear Medicine & Medical Imaging | Pharmacology & Pharmacy | Oncology | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Radioisotopes - pharmacokinetics | Radiotherapy Planning, Computer-Assisted - methods | Humans | Lung Neoplasms - metabolism | Yttrium Radioisotopes - pharmacokinetics | Liver Neoplasms - chemistry | Bone Neoplasms - metabolism | Computer Simulation | Water - chemistry | Bone Neoplasms - chemistry | Lutetium - chemistry | Radiometry - methods | Lutetium - pharmacokinetics | Phosphorus Radioisotopes - pharmacokinetics | Lung Neoplasms - chemistry | Bone Neoplasms - diagnostic imaging | Organ Specificity | Liver Neoplasms - diagnostic imaging | Phosphorus Radioisotopes - chemistry | Algorithms | Liver Neoplasms - metabolism | Radionuclide Imaging - methods | Lung Neoplasms - diagnostic imaging | Monte Carlo Method | Radioisotopes - chemistry | Yttrium Radioisotopes - chemistry | Spleen | Nuclear medicine | Dosimeters | Fourier transforms | Medical imaging | Kidneys | Computer simulation | Liver | Phosphorus | Tissues | Lutetium | Kernels | Simulation | Lungs | Mathematical analysis | Intestine | Beta rays | Clinical medicine | Dosimetry | Yttrium | Drug dosages | Methods
Journal Article
Details down arrow
6. Full Text Pulsed high intensity focused ultrasound increases penetration and therapeutic efficacy of monoclonal antibodies in murine xenograft tumors
by Wang, Shutao and Shin, In Soo and Hancock, Hilary and Jang, Beom-su and Kim, Hyung-sub and Lee, Sang Myung and Zderic, Vesna and Frenkel, Victor and Pastan, Ira and Paik, Chang H and Dreher, Matthew R
Journal of controlled release, ISSN 0168-3659, 08/2012, Volume 162, Issue 1, pp. 218 - 224
Binding site barrier | Monoclonal antibodies | Penetration | Pulsed-HIFU | Radioimmunotherapy | Pharmacology & Pharmacy | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Chemistry, Multidisciplinary | Science & Technology | Pharmaceutical technology. Pharmaceutical industry | Biological and medical sciences | Medical sciences | General pharmacology | Pharmacology. Drug treatments | Humans | Antibodies, Monoclonal - pharmacokinetics | Immunoconjugates - pharmacokinetics | Antibodies, Monoclonal - therapeutic use | Transplantation, Heterologous | Yttrium Radioisotopes - pharmacokinetics | Immunoconjugates - administration & dosage | Ultrasonic Therapy - methods | Yttrium Radioisotopes - administration & dosage | Immunoconjugates - immunology | Neoplasms - therapy | Animals | Antibodies, Monoclonal - administration & dosage | Mice, Nude | Neoplasms - immunology | Cell Line, Tumor | Immunoconjugates - therapeutic use | Radioimmunotherapy - methods | Mice | Neoplasms - pathology | Yttrium Radioisotopes - therapeutic use | Antibodies, Monoclonal - immunology | Yttrium Radioisotopes - immunology | Antigens | Health aspects | Analysis | Immunotherapy | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Preclinical animal research on therapy dosimetry with dual isotopes
by Konijnenberg, Mark and Jong, Marion
European journal of nuclear medicine and molecular imaging, ISSN 1619-7070, 05/2011, Volume 38, Issue SUPPL. 1, pp. 19 - 27
Radionuclide therapy | Dose-effect models | Radiation dosimetry | Medicine & Public Health | Orthopedics | Oncology | Nuclear Medicine | Imaging / Radiology | Cardiology | Dose–effect models | Life Sciences & Biomedicine | Radiology, Nuclear Medicine & Medical Imaging | Science & Technology | Lutetium - pharmacokinetics | Radiotherapy Dosage | Drug Evaluation, Preclinical - methods | Radioisotopes - pharmacokinetics | Radioisotopes - therapeutic use | Rats | Yttrium Radioisotopes - pharmacokinetics | Indium Radioisotopes - pharmacokinetics | Radiation Dosage | Lutetium - administration & dosage | Yttrium Radioisotopes - administration & dosage | Animals | Indium Radioisotopes - administration & dosage | Radioisotopes - administration & dosage | Indium Radioisotopes - therapeutic use | Neoplasms - radiotherapy | Lutetium - therapeutic use | Radiometry - methods | Dose-Response Relationship, Radiation | Yttrium Radioisotopes - therapeutic use | Radiopharmaceuticals - therapeutic use | Peptides | Radiation | Tumors | Nuclear medicine | Radiation therapy | Laboratory animals | Isotopes | Index Medicus | Review
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Biodistribution, Pharmacokinetics, and Dosimetry of 177 Lu-, 90 Y-, and 111 In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177 Lu-DOTATATE: The Mass Effect
by Nicolas, Guillaume P and Mansi, Rosalba and McDougall, Lisa and Kaufmann, Jens and Bouterfa, Hakim and Wild, Damian and Fani, Melpomeni
The Journal of nuclear medicine (1978), ISSN 0161-5505, 09/2017, Volume 58, Issue 9, pp. 1435 - 1441
Octreotide - analogs & derivatives | Humans | Organometallic Compounds - pharmacokinetics | Peptides, Cyclic - pharmacology | Octreotide - pharmacokinetics | Octreotide - pharmacology | Peptides, Cyclic - pharmacokinetics | Tissue Distribution | Receptors, Somatostatin - agonists | Coordination Complexes - pharmacokinetics | Animals | HEK293 Cells | Coordination Complexes - pharmacology | Isotope Labeling | Female | Radiometry | Receptors, Somatostatin - antagonists & inhibitors | Mice | Yttrium Radioisotopes | Indium Radioisotopes | Organometallic Compounds - pharmacology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text 89Zr Immuno-PET: Comprehensive Procedures for the Production of 89Zr-Labeled Monoclonal Antibodies
by Verel, Iris and Visser, Gerard W.M and Boellaard, Ronald and Stigter-van Walsum, Marijke and Snow, Gordon B and van Dongen, Guus A.M.S
The Journal of nuclear medicine (1978), ISSN 0161-5505, 08/2003, Volume 44, Issue 8, pp. 1271 - 1281
Xenograft-bearing nude mice | Radiology Nuclear Medicine and imaging | PET | Tumor detection | Radioimmunoconjugates | Biological and medical sciences | Medical sciences | Radioisotopes - pharmacokinetics | Radioisotopes - isolation & purification | Humans | Lung Neoplasms | Radiopharmaceuticals - chemical synthesis | Feasibility Studies | Tissue Distribution | Zirconium - pharmacokinetics | Sensitivity and Specificity | Zirconium - chemistry | Female | Radioimmunodetection - methods | Antibodies, Monoclonal - chemistry | Radiopharmaceuticals - isolation & purification | Reproducibility of Results | Radiopharmaceuticals - pharmacokinetics | Drug Stability | Carcinoma, Non-Small-Cell Lung - metabolism | Antibodies, Monoclonal - pharmacokinetics | Tomography, Emission-Computed - methods | Organ Specificity | Isotope Labeling - methods | Animals | Mice, Nude | Zirconium - isolation & purification | Carcinoma, Non-Small-Cell Lung - diagnostic imaging | Mice | Radioisotopes - chemistry | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia
by Pagel, John M and Matthews, Dana C and Kenoyer, Aimee and Hamlin, Donald K and Wilbur, Daniel S and Fisher, Darrell R and Gopal, Ajay K and Lin, Yukang and Saganic, Laura and Appelbaum, Frederick R and Press, Oliver W and Pacific Northwest National Lab. (PNNL), Richland, WA (United States)
Cancer research (Chicago, Ill.), ISSN 0008-5472, 01/2009, Volume 69, Issue 1, pp. 185 - 192
Life Sciences & Biomedicine | Oncology | Science & Technology | Humans | Male | Yttrium Radioisotopes - pharmacokinetics | Leukemia, Myeloid - radiotherapy | Yttrium Radioisotopes - administration & dosage | Lymphoid Tissue - immunology | Leukocyte Common Antigens - immunology | Tissue Distribution | Immunotoxins - administration & dosage | Radioimmunotherapy - methods | Female | Antibodies, Monoclonal - immunology | Biotin - administration & dosage | Immunotoxins - immunology | Biotin - pharmacokinetics | Antibodies, Monoclonal - pharmacokinetics | Leukemia, Myeloid - immunology | Lymphoid Tissue - metabolism | Organometallic Compounds - pharmacokinetics | Indium Radioisotopes - pharmacokinetics | Xenograft Model Antitumor Assays | Animals | Antibodies, Monoclonal - administration & dosage | Indium Radioisotopes - administration & dosage | Leukemia, Myeloid - metabolism | Immunotoxins - pharmacokinetics | Mice | Mice, Inbred BALB C | Biotin - analogs & derivatives | Organometallic Compounds - administration & dosage | Index Medicus | PATIENTS | MONOCLONAL ANTIBODIES | NEOPLASMS | LYMPH NODES | RADIOIMMUNOTHERAPY | RADIOISOTOPES | ANTIGENS | TUMOR CELLS | IN VIVO | 60 APPLIED LIFE SCIENCES | DISEASES | THERAPY | RADIATIONS | RADIOLOGY AND NUCLEAR MEDICINE | TARGETS | MICE | MYELOID LEUKEMIA | LEUKEMIA | BLOOD | leukemia | CD45 | Radioimmunotherapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Radiolabeling morpholinos with 90Y, 111In, 188Re and 99mTc
by Liu, Chang-bin and Liu, Guo-zheng and Liu, Ning and Zhang, Y.u-min and He, Jiang and Rusckowski, Mary and Hnatowich, Donald J
Nuclear medicine and biology, ISSN 0969-8051, 2003, Volume 30, Issue 2, pp. 207 - 214
Radiolabeling | MORF | Rhenium-188 | Yttrium-90 | Indium-111 | Biological and medical sciences | Medical sciences | Radioisotopes - pharmacokinetics | Oligonucleotides - therapeutic use | Humans | Male | Yttrium Radioisotopes - pharmacokinetics | Oligonucleotides - pharmacokinetics | Rhenium - pharmacokinetics | Tissue Distribution | Yttrium Radioisotopes - therapeutic use | Technetium - chemistry | Technetium - pharmacokinetics | Radioisotopes - therapeutic use | Radiopharmaceuticals - chemistry | Radiopharmaceuticals - pharmacokinetics | Indium Radioisotopes - chemistry | Indium Radioisotopes - pharmacokinetics | Organ Specificity | Oligonucleotides - chemical synthesis | Isotope Labeling - methods | Technetium - therapeutic use | Animals | Radiotherapy - methods | Indium Radioisotopes - therapeutic use | Mice | Rhenium - chemistry | Rhenium - therapeutic use | Radioisotopes - chemistry | Radiopharmaceuticals - therapeutic use | Yttrium Radioisotopes - chemistry | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential
by Koi, Lydia and Bergmann, Ralf and Brüchner, Kerstin and Pietzsch, Jens and Pietzsch, Hans-Jürgen and Krause, Mechthild and Steinbach, Jörg and Zips, Daniel and Baumann, Michael
Radiotherapy and oncology, ISSN 0167-8140, 2013, Volume 110, Issue 2, pp. 362 - 369
Hematology, Oncology and Palliative Medicine | Combined treatment | Radiotherapy | Cetuximab | Epidermal growth factor receptor (EGFR) inhibition | Radioimmunotherapy | Oncology | Life Sciences & Biomedicine | Radiology, Nuclear Medicine & Medical Imaging | Science & Technology | Radiopharmaceuticals - immunology | Humans | Male | Yttrium Radioisotopes - pharmacokinetics | Pentetic Acid - analogs & derivatives | Carcinoma, Squamous Cell - radiotherapy | Yttrium Radioisotopes - administration & dosage | Tissue Distribution | Pentetic Acid - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Immunotoxins - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Isothiocyanates - chemistry | Female | Receptor, Epidermal Growth Factor - immunology | Immunotoxins - immunology | Random Allocation | Carcinoma, Squamous Cell - immunology | Radiopharmaceuticals - administration & dosage | Animals | Carcinoma, Squamous Cell - drug therapy | Mice, Nude | Cell Line, Tumor | Immunotoxins - pharmacokinetics | Mice | Antibodies, Monoclonal, Humanized - immunology | Yttrium Radioisotopes - chemistry | Viral antibodies | Antibodies | Immunotherapy | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Melanoma-Targeting Property of Y-90-Labeled Lactam-Cyclized alpha-Melanocyte-Stimulating Hormone Peptide
by Xu, Jingli and Yang, Jianquan and Gonzalez, Rene and Fisher, Darrell R and Miao, Yubin
Cancer biotherapy & radiopharmaceuticals, ISSN 1084-9785, 11/2019, Volume 34, Issue 9, pp. 597 - 603
Life Sciences & Biomedicine | Radiology, Nuclear Medicine & Medical Imaging | Pharmacology & Pharmacy | Oncology | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Radiopharmaceuticals - chemistry | Radiopharmaceuticals - pharmacokinetics | alpha-MSH - chemistry | Heterocyclic Compounds, 1-Ring - pharmacokinetics | alpha-MSH - pharmacokinetics | Mice, Inbred C57BL | Tomography, Emission-Computed, Single-Photon | Melanoma, Experimental - pathology | Melanoma, Experimental - metabolism | Yttrium Radioisotopes - pharmacokinetics | Radiopharmaceuticals - chemical synthesis | Tissue Distribution | Xenograft Model Antitumor Assays | Animals | Heterocyclic Compounds, 1-Ring - chemistry | Cell Line, Tumor | Lactams - pharmacokinetics | Melanoma, Experimental - diagnostic imaging | Mice | Molecular Structure | Lactams - chemistry | Yttrium Radioisotopes - chemistry | Binding | Efflux | Evaluation | Melanocyte-stimulating hormone | Internalization | Melanoma | Melanocortin | Amides | a-Melanocyte-stimulating hormone | Yttrium isotopes | Tumors | Bearing
Journal Article
Details down arrow